The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwNHL 2016 | Novel immunotherapies and liquid biopsies – highlights from iwNHL 2016
Anton Hagenbeek, MD, PhD of the University of Amsterdam, Netherlands highlights the sessions on novel immunotherapies and liquid biopsies from the 2016 International Workshop on Non-Hodgkin Lymphoma (iwNHL) meeting held in San Diego, CA. Prof. Hagenbeek mentions CAR T-cells, the new generation of antibodies and new checkpoint inhibitors, as well as the session on the detection of tumor DNA in the circulation and minimal residual disease (MRD).
